Case number 2021-1729
AstraZeneca AB v. Mylan Pharmaceuticals Inc. > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Mar 9, 2022 | 65 | Mandate issued to the United States District Court for the Northern District of West Virginia. Service as of this date by the Clerk of Court. [835734] [MVH] [Entered: 03/09/2022 11:51 AM] (1) |
| Mar 2, 2022 | 64 | ORDER filed denying [51] petition for panel rehearing and rehearing en banc filed by AstraZeneca AB and AstraZeneca Pharmaceuticals LP. By: Per Curiam. Service as of this date by the Clerk of Court. [834247] [MVH] [Entered: 03/02/2022 09:34 AM] (2) |
| Feb 14, 2022 | 63 | 18 paper copies of Doc. No. [62] received from Appellants Kindeva Drug Delivery L.P. and Mylan Pharmaceuticals Inc.. [831119] [VDW] [Entered: 02/15/2022 09:26 AM] (0) |
| Feb 11, 2022 | 62 | Confidential Response filed by Appellants Mylan Pharmaceuticals Inc. and Kindeva Drug Delivery L.P. corresponding to Doc. No. [61]. Service: 02/11/2022 by email. [830765] [21-1729] [Andrew Dufresne] [Entered: 02/11/2022 03:54 PM] (0) |
| Feb 11, 2022 | 61 | RESPONSE of Appellants Mylan Pharmaceuticals Inc. and Kindeva Drug Delivery L.P. to Doc No. [51], [51]. Service: 02/11/2022 by clerk. [830764] [21-1729] [Andrew Dufresne] [Entered: 02/11/2022 03:48 PM] (30) |
| Feb 10, 2022 | 60 | The court invites a response from Appellants Kindeva Drug Delivery L.P. and Mylan Pharmaceuticals Inc. to the petition [51]. Response due 02/24/2022. Service as of this date by the Clerk of Court. [830388] [MVH] [Entered: 02/10/2022 12:43 PM] (1) |
| Feb 7, 2022 | 59 | 18 paper copies of Doc. No. [58] received from Amicus Curiae Pharmaceutical Research and Manufacturers of America. [829395] [VDW] [Entered: 02/07/2022 02:39 PM] (0) |
| Feb 4, 2022 | 58 | AMICUS BRIEF FILED by Pharmaceutical Research and Manufacturers of America. Service: 02/04/2022 by email. [829100] [MVH] [Entered: 02/04/2022 02:37 PM] (20) |
| Feb 4, 2022 | 57 | ORDER filed granting motion leave to file amicus brief on en banc or rehearing petition [56]. By: Per Curiam. Service as of this date by the Clerk of Court. [829098] [MVH] [Entered: 02/04/2022 02:34 PM] (2) |
| Feb 4, 2022 | 56 | MOTION of Amicus Curiae Pharmaceutical Research and Manufacturers of America for leave to file amicus brief in support of Appellees AstraZeneca AB and AstraZeneca Pharmaceuticals LP on petition for panel rehearing [51], petition for en banc rehearing [51]. Service: 02/04/2022 by email. [829036] [21-1729] [Thomas Saunders] [Entered: 02/04/2022 11:01 AM] (28) |
| Feb 4, 2022 | 55 | Certificate of Interest for Amicus Curiae Pharmaceutical Research and Manufacturers of America. Service: 02/04/2022 by email. [829035] [21-1729] [Thomas Saunders] [Entered: 02/04/2022 10:57 AM] (3) |
| Feb 4, 2022 | 54 | Entry of appearance for Thomas G. Saunders; Reshma C. Gogineni; David E. Korn as counsel for Amicus Curiae Pharmaceutical Research and Manufacturers of America. Service: 02/04/2022 by email. [829033] [21-1729] [Thomas Saunders] [Entered: 02/04/2022 10:56 AM] (2) |
| Jan 28, 2022 | 53 | 18 paper copies of Doc. No. [52], received from Appellees AstraZeneca AB and AstraZeneca Pharmaceuticals LP. [827723] [VDW] [Entered: 01/28/2022 02:45 PM] (0) |
| Jan 21, 2022 | 52 | Confidential Petition for panel rehearing, for en banc rehearing filed by Appellees AstraZeneca AB and AstraZeneca Pharmaceuticals LP corresponding to Doc. No. [51], corresponding to Doc. No. [51]. Service: 01/21/2022 by email. [826225] [21-1729] [David Berl] [Entered: 01/21/2022 08:47 PM] (0) |
| Jan 21, 2022 | 51 | Petition for panel rehearing, for en banc rehearing filed by Appellees AstraZeneca AB and AstraZeneca Pharmaceuticals LP. Service: 01/21/2022 by email. [826224] [21-1729] [David Berl] [Entered: 01/21/2022 08:38 PM] (71) |
| Dec 28, 2021 | 50 | ORDER filed granting motion to extend time to file petition for rehearing/en banc [49] filed by Appellees AstraZeneca AB and AstraZeneca Pharmaceuticals LP. No further extensions. Petition for Rehearing due on or before 01/21/2022. By: Merits Panel (Per Curiam). Service as of this date by the Clerk of Court. [821529] [MVH] [Entered: 12/28/2021 12:24 PM] (2) |
| Dec 23, 2021 | 0 | ASTRAZENECA AB v. MYLAN PHARMACEUTICALS INC. [OPINION] [precedential] (0) |
| Dec 22, 2021 | 49 | MOTION of Appellees AstraZeneca AB and AstraZeneca Pharmaceuticals LP to extend the time to file a Combined Petition for Panel Rehearing and Rehearing En Banc until 01/21/2022. Service: 12/22/2021 by email. [820500] [21-1729] [David Berl] [Entered: 12/22/2021 11:24 AM] (12) |
| Dec 8, 2021 | 48 | JUDGMENT. AFFIRMED-IN-PART, VACATED-IN-PART, AND REMANDED. Terminated on the merits after oral argument. COSTS: No Costs. Mandate to issue in due course. For information regarding costs, petitions for rehearing, and petitions for writs of certiorari click here. Service as of this date by the Clerk of Court. [817075] [MJL] [Entered: 12/08/2021 10:21 AM] (1) |
| Dec 8, 2021 | 47 | OPINION filed for the court by Taranto, Circuit Judge; Hughes, Circuit Judge and Stoll, Circuit Judge. Opinion dissenting in part filed by Circuit Judge Taranto. Precedential Opinion. Service as of this date by the Clerk of Court. [817074] [MJL] [Entered: 12/08/2021 10:20 AM] (38) |
| Dec 7, 2021 | 46 | RESPONSE of Appellants Mylan Pharmaceuticals Inc., Kindeva Drug Delivery L.P. and Appellees AstraZeneca AB and AstraZeneca Pharmaceuticals LP to Doc. No. [45]. Service: 12/07/2021 by clerk. [816729] [21-1729] [Andrew Dufresne] [Entered: 12/07/2021 10:46 AM] (1) |
| Dec 1, 2021 | 45 | Clerk's letter (FILED UNDER SEAL) to the parties regarding confidential material. Response due on or before 12/07/2021. Service as of this date by the Clerk of Court. [815504] [MJL] [Entered: 12/01/2021 09:20 AM] (0) |
| Aug 31, 2021 | 44 | Submitted after ORAL ARGUMENT to Panel: Taranto, Circuit Judge; Hughes, Circuit Judge and Stoll, Circuit Judge.Arguing counsel: Andrew Dufresne for Mylan Pharmaceuticals Inc. and Kindeva Drug Delivery L.P. and David I. Berl for AstraZeneca AB and AstraZeneca Pharmaceuticals LP.Oral Argument Audio available here. [796406] [JCP] [Entered: 08/31/2021 04:17 PM] (0) |
| Aug 16, 2021 | 43 | Response to notice of oral argument from Appellees AstraZeneca AB and AstraZeneca Pharmaceuticals LP. Service: 08/16/2021 by email. [793138] [21-1729] [David Berl] [Entered: 08/16/2021 09:19 PM] (3) |
| Aug 16, 2021 | 42 | Response to notice of oral argument from Appellants Mylan Pharmaceuticals Inc. and Kindeva Drug Delivery L.P.. Service: 08/16/2021 by clerk. [793106] [21-1729] [Andrew Dufresne] [Entered: 08/16/2021 06:31 PM] (3) |
| Aug 12, 2021 | 41 | Counsel are advised that the Federal Circuit has issued Revised Protocols for In-Person Arguments. All arguing counsel, including counsel who have already filed a Response to Notice of Oral Argument, must file revised Form 33A no later than 08/16/2021. Form 33A may be attached to the Response to Notice of Oral Argument or filed as Other Document. [792190] [MJL] [Entered: 08/12/2021 10:32 AM] (0) |
| Jul 21, 2021 | 40 | NOTICE OF ORAL ARGUMENT. Panel: 2109C. Case scheduled August 31, 2021. Response to Notice of Oral Argument due: 08/16/2021. Please review the attached Notice. The response to notice of oral argument form can be found here. The Oral Argument Guide can be found here. Service as of this date by the Clerk of Court. [787801] [JCP] [Entered: 07/21/2021 05:00 PM] (2) |
| Jun 21, 2021 | 38 | Notice from Appellants Mylan Pharmaceuticals Inc. and Kindeva Drug Delivery L.P. regarding conflicts with oral argument. None. Service: 06/21/2021 by email. [781581] [21-1729] [Nathan Kelley] [Entered: 06/21/2021 11:37 PM] (0) |
| Jun 21, 2021 | 37 | Notice from Appellees AstraZeneca AB and AstraZeneca Pharmaceuticals LP regarding conflicts with oral argument. Service: 06/21/2021 by email. [781579] [21-1729] [David Berl] [Entered: 06/21/2021 11:29 PM] (3) |
| Jun 17, 2021 | 36 | 6 paper copies of Doc. No. [29], [24], [13] received from Appellants Kindeva Drug Delivery L.P. and Mylan Pharmaceuticals Inc.. [781056] [VDW] [Entered: 06/17/2021 04:16 PM] (0) |
| Jun 16, 2021 | 39 | 6 paper copies of Doc. No. [23] received from Appellees AstraZeneca AB and AstraZeneca Pharmaceuticals LP. [786196] [VDW] [Entered: 07/14/2021 01:21 PM] (0) |
| Jun 14, 2021 | 33 | Corrected Certificate of Service filed by Appellants Mylan Pharmaceuticals Inc. and Kindeva Drug Delivery L.P. to Doc No. [29]. Service: 06/14/2021 by clerk. [780053] [21-1729] [Andrew Dufresne] [Entered: 06/14/2021 12:09 PM] (2) |
| Jun 14, 2021 | 34 | Notice to counsel: The Clerk's Office directs that outstanding paper copies of all briefs and appendices in this case must be submitted on or before June 21, 2021. See Administrative Order No. 20-01 (Mar. 20, 2020). [780065] [EKD] [Entered: 06/14/2021 12:56 PM] (0) |
| Jun 14, 2021 | 35 | Notice to Advise of Scheduling Conflicts. Arguing counsel must advise of, and show good cause for, any scheduling conflicts during the upcoming court session months listed in the attached notice. The Response to Notice to Advise of Scheduling Conflicts can be found here. The Oral Argument Guide can be found here. [780066] [EKD] [Entered: 06/14/2021 12:56 PM] (1) |
| Jun 11, 2021 | 32 | Certificate of Compliance with Fed. Cir. R. 25.1(c)(2) for Appellees Astrazeneca AB and AstraZeneca Pharmaceuticals LP. Service: 06/11/2021 by email. [779898] [21-1729] [David Berl] [Entered: 06/11/2021 06:56 PM] (3) |
| Jun 11, 2021 | 31 | Certificate of Compliance with Fed. Cir. R. 25.1(c)(2) for Appellants Mylan Pharmaceuticals Inc. and Kindeva Drug Delivery L.P.. Service: 06/11/2021 by clerk. [779897] [21-1729] [Andrew Dufresne] [Entered: 06/11/2021 06:42 PM] (2) |
| Jun 11, 2021 | 30 | MODIFIED ENTRY: APPENDIX FILED by Appellants Kindeva Drug Delivery L.P. and Mylan Pharmaceuticals Inc. Service: 06/11/2021 by clerk. [779896] --[Edited 06/14/2021 by EKD - compliance review complete] [Andrew Dufresne] [Entered: 06/11/2021 06:40 PM] (1057) |
| Jun 11, 2021 | 29 | MODIFIED ENTRY: CONFIDENTIAL APPENDIX FILED by Appellants Kindeva Drug Delivery L.P. and Mylan Pharmaceuticals Inc. Service: 06/11/2021 by email. [779894]--[Edited 06/14/2021 by EKD - compliance review complete] [Andrew Dufresne] [Entered: 06/11/2021 06:32 PM] (0) |
| Jun 7, 2021 | 28 | Joint Statement of Compliance with Fed. Cir. R. 33 for Appellees Astrazeneca AB, AstraZeneca Pharmaceuticals LP and Appellants Kindeva Drug Delivery L.P. and Mylan Pharmaceuticals Inc.. Service: 06/07/2021 by email. [778872] [21-1729] [Nathan Kelley] [Entered: 06/07/2021 04:02 PM] (3) |
| Jun 7, 2021 | 27 | **TEXT ONLY** ORDER extending the time to 06/11/2021 to resolve confidentiality issues pursuant to Federal Circuit Rule 26(b)(4) and file the appendix. Service as of this date by the Clerk of Court. This order has been issued without an attached document and is official and binding. [778871] [EKD] [Entered: 06/07/2021 04:02 PM] (0) |
| Jun 7, 2021 | 26 | Request to extend time to file joint appendix to resolve confidentiality issues under Federal Circuit Rule 26(b)(4) for Appellants Kindeva Drug Delivery L.P. and Mylan Pharmaceuticals Inc.. Service: 06/07/2021 by clerk. [778803] [21-1729] [Andrew Dufresne] [Entered: 06/07/2021 02:18 PM] (8) |
| Jun 3, 2021 | 25 | Entry of appearance for Emily J. Greb as counsel for Appellants Kindeva Drug Delivery L.P. and Mylan Pharmaceuticals Inc.. Service: 06/03/2021 by clerk. [778408] [21-1729] [Emily Greb] [Entered: 06/03/2021 04:16 PM] (1) |
| Jun 2, 2021 | 24 | MODIFIED ENTRY: REPLY BRIEF FILED by Appellants Kindeva Drug Delivery L.P. and Mylan Pharmaceuticals Inc. Service: 06/02/2021 by email. [778227] --[Edited 06/04/2021 by EKD - compliance review complete] [Nathan Kelley] [Entered: 06/02/2021 09:38 PM] (40) |
| May 20, 2021 | 23 | MODIFIED ENTRY: CONFIDENTIAL RESPONSE BRIEF FILED by Appellees AstraZeneca Pharmaceuticals LP and Astrazeneca AB. Service: 05/20/2021 by email. [776254]--[Edited 05/21/2021 by EKD - compliance review complete] [David Berl] [Entered: 05/20/2021 02:03 PM] (0) |
| May 20, 2021 | 22 | MODIFIED ENTRY: CORRECTED RESPONSE BRIEF FILED by Appellees AstraZeneca Pharmaceuticals LP and Astrazeneca AB. Service: 05/20/2021 by email. [776250] --[Edited 05/21/2021 by EKD - compliance review complete] [David Berl] [Entered: 05/20/2021 02:00 PM] (94) |
| May 20, 2021 | 21 | NOTICE OF NON-COMPLIANCE: The submissions of Appellees AstraZeneca Pharmaceuticals LP and Astrazeneca AB, Confidential and Non-Confidential Response Briefs [19], [20], are not in compliance with the rules of this court (see attached). Compliant documents are due on 05/27/2021. Service as of this date by the Clerk of Court. [776203] [EKD] [Entered: 05/20/2021 11:35 AM] (1) |
| May 17, 2021 | 20 | CONFIDENTIAL RESPONSE BRIEF FILED by Appellees Astrazeneca AB and AstraZeneca Pharmaceuticals LP. Service: 05/17/2021 by email. [775533] [21-1729] This document is non-compliant. See Doc No. [21] [David Berl] [Entered: 05/17/2021 09:15 PM] (0) |
| May 17, 2021 | 19 | RESPONSE BRIEF FILED by Appellees Astrazeneca AB and AstraZeneca Pharmaceuticals LP. Service: 05/17/2021 by email. [775532] [21-1729] This document is non-compliant. See Doc No. [21] [David Berl] [Entered: 05/17/2021 09:02 PM] (94) |
| May 17, 2021 | 18 | Amended Certificate of Interest for Appellees Astrazeneca AB and AstraZeneca Pharmaceuticals LP. Service: 05/17/2021 by email. [775531] [21-1729] [David Berl] [Entered: 05/17/2021 08:56 PM] (4) |
| May 10, 2021 | 17 | Amended Entry of appearance for David I. Berl; Jessica Bodger Rydstrom; Jessica Palmer Ryen; Kevin D. Hoagland-Hanson; Arthur John Argall III; Christopher Neil Sipes; Gary Rubman; Douglas Alexander Behrens as counsel for Appellees Astrazeneca AB and AstraZeneca Pharmaceuticals LP. Service: 05/10/2021 by email. [774046] [21-1729] [Kevin Hoagland-Hanson] [Entered: 05/10/2021 02:07 PM] (3) |
| Apr 16, 2021 | 16 | Entry of appearance for Vinny Lee as counsel for Appellants Kindeva Drug Delivery L.P. and Mylan Pharmaceuticals Inc.. Service: 04/16/2021 by clerk, email. [769385] [21-1729] [Vinny Lee] [Entered: 04/16/2021 04:21 PM] (1) |
| Apr 13, 2021 | 15 | Corrected Certificate of Service filed by Appellants Mylan Pharmaceuticals Inc. and Kindeva Drug Delivery L.P. to Doc No. [13]. Service: 04/06/2021 by email. [768272] [21-1729] [Andrew Dufresne] [Entered: 04/13/2021 11:36 AM] (1) |
| Apr 6, 2021 | 14 | MODIFIED ENTRY: OPENING BRIEF FILED by Appellants Kindeva Drug Delivery L.P. and Mylan Pharmaceuticals Inc. Service: 04/06/2021 by clerk. [767123] --[Edited 04/13/2021 by EKD - compliance review complete] [Andrew Dufresne] [Entered: 04/06/2021 06:49 PM] (223) |
| Apr 6, 2021 | 13 | MODIFIED ENTRY: CONFIDENTIAL OPENING BRIEF FILED by Appellants Kindeva Drug Delivery L.P. and Mylan Pharmaceuticals Inc. Service: 04/06/2021 by email. [767121]--[Edited 04/13/2021 by EKD - compliance review complete] [Andrew Dufresne] [Entered: 04/06/2021 06:45 PM] (0) |
| Mar 26, 2021 | 12 | Docketing Statement for the Appellants Mylan Pharmaceuticals Inc. and Kindeva Drug Delivery L.P.. Service: 03/26/2021 by clerk. [765122] [21-1729] [Andrew Dufresne] [Entered: 03/26/2021 03:05 PM] (2) |
| Mar 26, 2021 | 11 | Docketing Statement for the Appellees Astrazeneca AB and AstraZeneca Pharmaceuticals LP. Service: 03/26/2021 by email. [764920] [21-1729] [David Berl] [Entered: 03/26/2021 10:25 AM] (2) |
| Mar 26, 2021 | 10 | Certificate of Interest for Appellees Astrazeneca AB and AstraZeneca Pharmaceuticals LP. Service: 03/26/2021 by email. [764915] [21-1729] [David Berl] [Entered: 03/26/2021 10:23 AM] (4) |
| Mar 26, 2021 | 9 | Entry of appearance for David I. Berl; Jessica Palmer Ryen; Christopher Neil Sipes; Gary Rubman; Douglas Alexander Behrens as counsel for Appellees Astrazeneca AB and AstraZeneca Pharmaceuticals LP. Service: 03/26/2021 by email. [764911] [21-1729] [David Berl] [Entered: 03/26/2021 10:22 AM] (2) |
| Mar 24, 2021 | 8 | Corrected Certificate of Interest for Appellants Mylan Pharmaceuticals Inc. and Kindeva Drug Delivery L.P.. Service: 03/24/2021 by email. [764578] [21-1729] [Shannon Bloodworth] [Entered: 03/24/2021 05:07 PM] (3) |
| Mar 23, 2021 | 7 | ORDER granting [5] the motion. The appellants' opening brief is due no later than April 6, 2021; the appellees' response brief is due no later than May 17, 2021; the appellants' reply brief is due no later than June 2, 2021; and the joint appendix is due no later than June 7, 2021. Service as of this date by the Clerk of Court. [764245] [LMS] [Entered: 03/23/2021 03:08 PM] (2) |
| Mar 22, 2021 | 6 | NOTICE OF NON-COMPLIANCE: The submissions of Appellants Kindeva Drug Delivery L.P. and Mylan Pharmaceuticals Inc., Certificates of Interest [3], [4], are not in compliance with the rules of this court (see attached). Compliant documents are due on 03/29/2021. Service as of this date by the Clerk of Court. [763692] [EKD] [Entered: 03/22/2021 09:44 AM] (1) |
| Mar 16, 2021 | 5 | MOTION of Appellants Mylan Pharmaceuticals Inc. and Kindeva Drug Delivery L.P. to set briefing schedule. Service: 03/16/2021 by email. [762776] [21-1729] [Shannon Bloodworth] [Entered: 03/16/2021 06:06 PM] (10) |
| Mar 16, 2021 | 4 | Certificate of Interest for Appellant Kindeva Drug Delivery L.P. Service: 03/16/2021 by email. [762775] [21-1729] This document is non-compliant. See Doc No. [6] [Shannon Bloodworth] [Entered: 03/16/2021 06:05 PM] (3) |
| Mar 16, 2021 | 3 | Certificate of Interest for Appellant Mylan Pharmaceuticals Inc. Service: 03/16/2021 by email. [762773] [21-1729] This document is non-compliant. See Doc No. [6] [Shannon Bloodworth] [Entered: 03/16/2021 06:03 PM] (3) |
| Mar 16, 2021 | 2 | Entry of appearance for Shannon M. Bloodworth; David L. Anstaett; Dan L. Bagatell; Andrew T. Dufresne; Nathan K. Kelley as counsel for Appellants Mylan Pharmaceuticals Inc. and Kindeva Drug Delivery L.P.. Service: 03/16/2021 by email. [762772] [21-1729] [Shannon Bloodworth] [Entered: 03/16/2021 06:00 PM] (2) |
| Mar 12, 2021 | 1 | Appeal docketed. Received: 03/10/2021. [761829]Entry of Appearance is due on 03/26/2021. Certificate of Interest is due on 03/26/2021. Docketing Statement is due on 03/26/2021. Appellants' brief is due on 05/11/2021. [EKD] [Entered: 03/12/2021 10:37 AM] (140) |
